Old Web
English
Sign In
Acemap
>
authorDetail
>
Xavier C. Badoux
Xavier C. Badoux
Ministry of Health (New South Wales)
Oncology
Venetoclax
Minimal residual disease
Ibrutinib
Medicine
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
2021
Journal of Clinical Oncology
William G. Wierda
John N. Allan
Tanya Siddiqi
Thomas J. Kipps
Stephen Opat
Alessandra Tedeschi
Xavier C. Badoux
Bryone J. Kuss
Sharon Jackson
Carol Moreno
Ryan Jacobs
John M. Pagel
Ian W. Flinn
Yvonne Pak
Cathy Zhou
Edith Szafer-Glusman
Joi Ninomoto
James P Dean
Danelle F. James
Paolo Ghia
Constantine S. Tam
Show All
Source
Cite
Save
Citations (0)
First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study
2021
Blood
Paolo Ghia
John N. Allan
Tanya Siddiqi
Thomas J. Kipps
Bryone J. Kuss
Stephen Opat
Ian W. Flinn
Xavier C. Badoux
Alessandra Tedeschi
Eva González-Barca
John M. Pagel
Ryan Jacobs
Jacqueline C. Barrientos
Edith Szafer-Glusman
Cathy Zhou
Joi Ninomoto
James P Dean
Constantine S. Tam
William G. Wierda
Show All
Source
Cite
Save
Citations (0)
1